

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE


76/c  
AB  
07/08/99

Attorney Docket No: 017283/0123

*In re* patent application of  
BENOIT, Patrick *et al.*

Serial No.: 09/240,675

Filed: February 2, 1999



Group Art Unit: 1641

Examiner: S. Devi

For: MONOCLONAL ANTIBODIES AGAINST THE INTERFERON RECEPTOR,  
WITH NEUTRALIZING ACTIVITY AGAINST TYPE 1 INTERFERON

**RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS  
FOR SEQUENCE DISCLOSURES UNDER 37 C.F.R. § 1.821(e)**

Assistant Commissioner for Patents  
Washington, D.C. 20231  
Box SEQUENCE

Sir:

In response to the Notice to Comply with Requirements for Sequence Disclosures mailed on May 26, 1999, applicants refer to the Sequence Listing and the computer readable form thereof filed on March 28, 1996 in parent application U.S. Serial No. 08/307,588, which contains sequence information identical to that of the present application. Applicants hereby request, therefore, that the Sequence Listing of the parent application be used to fulfill the sequence disclosure requirements for the application in caption pursuant to 37 C.F.R. § 1.821(e). Enclosed are copies of the Sequence Listing and Statement to Support Filing and Submission in accordance with 37 C.F.R. §§ 1.821-1.825, which were filed in the parent application.

Applicants respectfully request examination of the instant application on the merits in due course.

Respectfully submitted,

June 25, 1999  
Date

Bernhard D. Saxe  
Reg. No. 28,665

FOLEY & LARDNER  
3000 K Street, N.W., Suite 500  
Washington, D.C. 20007  
(202) 672-5300

UNITED STATES DEPARTMENT OF COMMERCE  
Patent and Trademark Office  
COMMISSIONER OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231

SERIAL NUMBER	FILING DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NO.
08/240,675	02/02/99	Benoit et al.	017283/0123

EXAMINER	
S. Devi, Ph.D.	
ART UNIT	PAPER NUMBER
1641	

DATE MAILED:

Please find below a communication from the EXAMINER in charge of this application  
Commissioner of Patents

- 1) This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 CFR 1.821 through 1.825 for the reason(s) set forth on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures.
  
- 2) APPLICANT IS GIVEN A ONE MONTH EXTENDABLE PERIOD OF TIME FROM THE DATE OF THIS LETTER WITHIN WHICH TO COMPLY WITH THE SEQUENCE RULES, 37 CFR 1.821 - 1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 CFR 1.821(g). Extensions of time may be obtained under the provisions of 37 CFR 1.136. In no case may an Applicant extend the period of reply beyond the SIX MONTH statutory period. Applicant is requested to return a copy of the attached Notice to Comply with the response.